The importance of klotho in phosphate metabolism and kidney disease

Nephrology

Volumn 19, Issue 8, 2014, Pages 439-449

  Tan, Sven Jean ^a,b   Smith, Edward R ^a   Hewitson, Tim D ^a,b   Holt, Stephen G ^a,b   Toussaint, Nigel D ^a,b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

acute kidney injury; cardiovascular disease; chronic kidney disease; fibroblast growth factor 23; klotho; phosphate

Indexed keywords

ANGIOTENSIN II; FIBROBLAST GROWTH FACTOR RECEPTOR; KLOTHO PROTEIN; MEMBRANE BOUND KLOTHO PROTEIN; MEMBRANE PROTEIN; PHOSPHATE; SOLUBLE KLOTHO PROTEIN; UNCLASSIFIED DRUG; BETA GLUCURONIDASE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23;

ACUTE KIDNEY FAILURE; CHRONIC KIDNEY DISEASE; HUMAN; INFLAMMATION; KIDNEY DISEASE; KIDNEY FIBROSIS; NONHUMAN; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROTEIN DETERMINATION; REGULATORY MECHANISM; REVIEW; TISSUE DISTRIBUTION; VASCULAR DISEASE; METABOLISM; PHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC;

FIBROBLAST GROWTH FACTORS; GLUCURONIDASE; HUMANS; PHOSPHATES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84904913280     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12268     Document Type: Review

References (127)

1. Couser WG, Remuzzi G, Mendis S, Tonelli M,. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 2011; 80: 1258-1270.
2. Block GA, Ix JH, Ketteler M, et al. Phosphate homeostasis in CKD: Report of a scientific symposium sponsored by the National Kidney Foundation. Am. J. Kidney Dis. 2013; 62: 457-473.
3. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. Suppl. 2009; 113: S1-130.
4. Berndt T, Kumar R,. Phosphatonins and the regulation of phosphate homeostasis. Annu. Rev. Physiol. 2007; 69: 341-359.
5. Bergwitz C, Juppner H,. Phosphate sensing. Adv. Chronic Kidney Dis. 2011; 18: 132-144.
6. Cundy T, Grey A, Reid IR,. Calcium, phosphate and magnesium. In:, Marshall WJ, Bangert SK, (eds). Clinical Biochemistry Metabolic and Clinical Aspects. Edinburgh: Churchill Livingstone Elsevier, 2008; 95-127.
7. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390: 45-51.
8. Kuro-o M,. Klotho in health and disease. Curr. Opin. Nephrol. Hypertens. 2012; 21: 362-368.
9. Yamashita T, Yoshioka M, Itoh N,. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem. Biophys. Res. Commun. 2000; 277: 494-498.
10. Consortium A,. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat. Genet. 2000; 26: 345-348.
11. Kuwahara N, Sasaki S, Kobara M, et al. HMG-CoA reductase inhibition improves anti-aging klotho protein expression and arteriosclerosis in rats with chronic inhibition of nitric oxide synthesis. Int. J. Cardiol. 2008; 123: 84-90.
12. Shimada T, Takeshita Y, Murohara T, et al. Angiogenesis and vasculogenesis are impaired in the precocious-aging klotho mouse. Circulation 2004; 110: 1148-1155.
13. Hu MC, Shiizaki K, Kuro-o M, Moe OW,. Fibroblast growth factor 23 and klotho: Physiology and pathophysiology of an endocrine network of mineral metabolism. Annu. Rev. Physiol. 2013; 75: 503-533.
14. Beenken A, Mohammadi M,. The structural biology of the FGF19 subfamily. Adv. Exp. Med. Biol. 2012; 728: 1-24.
15. Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J. Biol. Chem. 2006; 281: 6120-6123.
16. Nakatani T, Sarraj B, Ohnishi M, et al. In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23) -mediated regulation of systemic phosphate homeostasis. FASEB J. 2009; 23: 433-441.
17. Nakatani T, Ohnishi M, Razzaque MS,. Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model. FASEB J. 2009; 23: 3702-3711.
18. Kurosu H, Yamamoto M, Clark JD, et al. Suppression of aging in mice by the hormone klotho. Science 2005; 309: 1829-1833.
19. Kurosu H, Choi M, Ogawa Y, et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol. Chem. 2007; 282: 26687-26695.
20. Ogawa Y, Kurosu H, Yamamoto M, et al. BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc. Natl Acad. Sci. U.S.A. 2007; 104: 7432-7437.
21. Li SA, Watanabe M, Yamada H, Nagai A, Kinuta M, Takei K,. Immunohistochemical localization of klotho protein in brain, kidney, and reproductive organs of mice. Cell Struct. Funct. 2004; 29: 91-99.
22. Andrukhova O, Zeitz U, Goetz R, Mohammadi M, Lanske B, Erben RG,. FGF23 acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1/2-SGK1 signaling pathway. Bone 2012; 51: 621-628.
23. Matsumura Y, Aizawa H, Shiraki-Iida T, Nagai R, Kuro-o M, Nabeshima Y,. Identification of the human klotho gene and its two transcripts encoding membrane and secreted klotho protein. Biochem. Biophys. Res. Commun. 1998; 242: 626-630.
24. Chen CD, Podvin S, Gillespie E, Leeman SE, Abraham CR,. Insulin stimulates the cleavage and release of the extracellular domain of klotho by ADAM10 and ADAM17. Proc. Natl Acad. Sci. U.S.A. 2007; 104: 19796-19801.
25. Bloch L, Sineshchekova O, Reichenbach D, et al. Klotho is a substrate for alpha-, beta- and gamma-secretase. FEBS Lett. 2009; 583: 3221-3224.
26. Huang CL,. Regulation of ion channels by secreted klotho: Mechanisms and implications. Kidney Int. 2010; 77: 855-860.
27. Tohyama O, Imura A, Iwano A, et al. Klotho is a novel beta-glucuronidase capable of hydrolyzing steroid beta-glucuronides. J. Biol. Chem. 2004; 279: 9777-9784.
28. Cha SK, Ortega B, Kurosu H, Rosenblatt K, Kuro OM, Huang CL,. Removal of sialic acid involving klotho causes cell-surface retention of TRPV5 channel via binding to galectin-1. Proc. Natl Acad. Sci. U.S.A. 2008; 105: 9805-9810.
29. Cha SK, Hu MC, Kurosu H, Kuro-o M, Moe O, Huang CL,. Regulation of renal outer medullary potassium channel and renal K(+) excretion by klotho. Mol. Pharmacol. 2009; 76: 38-46.
30. Kuro-o M,. Klotho as a regulator of oxidative stress and senescence. Biol. Chem. 2008; 389: 233-241.
31. Hu MC, Shi M, Zhang J, et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J. Am. Soc. Nephrol. 2011; 22: 124-136.
32. Komaba H, Koizumi M, Tanaka H, et al. Effects of cinacalcet treatment on serum soluble klotho levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol. Dial. Transplant. 2012; 27: 1967-1969.
33. Sakan H, Nakatani K, Asai O, et al. Reduced renal alpha-klotho expression in CKD patients and its effect on renal phosphate handling and vitamin D metabolism. PLoS ONE 2014; 9: e86301.
34. Smith RC, O'Bryan LM, Farrow EG, et al. Circulating alphaKlotho influences phosphate handling by controlling FGF23 production. J. Clin. Invest. 2012; 122: 4710-4715.
35. Juppner H, Wolf M,. alphaKlotho: FGF23 coreceptor and FGF23-regulating hormone. J. Clin. Invest. 2012; 122: 4336-4339.
36. Yamazaki Y, Imura A, Urakawa I, et al. Establishment of sandwich ELISA for soluble alpha-klotho measurement: Age-dependent change of soluble alpha-klotho levels in healthy subjects. Biochem. Biophys. Res. Commun. 2010; 398: 513-518.
37. Heijboer AC, Blankenstein MA, Hoenderop J, de Borst MH, Vervloet MG, N. consortium. Laboratory aspects of circulating alpha-klotho. Nephrol. Dial. Transplant. 2013; 28: 2283-2287.
38. Golembiewska E, Safranow K, Kabat-Koperska J, Myslak M, Ciechanowski K,. Serum soluble klotho protein level is associated with residual diuresis in incident peritoneal dialysis patients. Acta Biochim. Pol. 2013; 60: 191-194.
39. Pavik I, Jaeger P, Ebner L, et al. Secreted klotho and FGF23 in chronic kidney disease stage 1 to 5: A sequence suggested from a cross-sectional study. Nephrol. Dial. Transplant. 2013; 28: 352-359.
40. Wan M, Smith C, Shah V, et al. Fibroblast growth factor 23 and soluble klotho in children with chronic kidney disease. Nephrol. Dial. Transplant. 2013; 28: 153-161.
41. Kim HR, Nam BY, Kim DW, et al. Circulating alpha-klotho levels in CKD and relationship to progression. Am. J. Kidney Dis. 2013; 61: 899-909.
42. Kitagawa M, Sugiyama H, Morinaga H, et al. A decreased level of serum soluble klotho is an independent biomarker associated with arterial stiffness in patients with chronic kidney disease. PLoS ONE 2013; 8: e56695.
43. Seiler S, Wen M, Roth HJ, et al. Plasma klotho is not related to kidney function and does not predict adverse outcome in patients with chronic kidney disease. Kidney Int. 2013; 83: 121-128.
44. Akimoto T, Kimura T, Watanabe Y, et al. The impact of nephrectomy and renal transplantation on serum levels of soluble klotho protein. Transplant. Proc. 2013; 45: 134-136.
45. Hryszko T, Rydzewska-Rosolowska A, Gozdzikiewicz J, et al. Cholecalciferol supplementation reduces soluble klotho concentration in hemodialysis patients. Pol. Arch. Med. Wewn. 2013; 123: 277-281.
46. Karalliedde J, Maltese G, Hill B, Viberti G, Gnudi L,. Effect of renin-angiotensin system blockade on soluble klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria. Clin. J. Am. Soc. Nephrol. 2013; 8: 1899-1905.
47. Lim SC, Liu JJ, Subramaniam T, Sum CF,. Elevated circulating alpha-klotho by angiotensin II receptor blocker losartan is associated with reduction of albuminuria in type 2 diabetic patients. J. Renin Angiotensin Aldosterone Syst. 2013; Epub ahead of print. doi: 10.1177/1470320313475905.
48. Pavik I, Jaeger P, Ebner L, et al. Soluble klotho and autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 2012; 7: 248-257.
49. Devaraj S, Syed B, Chien A, Jialal I,. Validation of an immunoassay for soluble klotho protein: Decreased levels in diabetes and increased levels in chronic kidney disease. Am. J. Clin. Pathol. 2012; 137: 479-485.
50. Kacso IM, Bondor CI, Kacso G,. Soluble serum klotho in diabetic nephropathy: Relationship to VEGF-A. Clin. Biochem. 2012; 45: 1415-1420.
51. Akimoto T, Shiizaki K, Sugase T, et al. The relationship between the soluble klotho protein and the residual renal function among peritoneal dialysis patients. Clin. Exp. Nephrol. 2012; 16: 442-447.
52. Yokoyama K, Imura A, Ohkido I, et al. Serum soluble alpha-klotho in hemodialysis patients. Clin. Nephrol. 2012; 77: 347-351.
53. Shimamura Y, Hamada K, Inoue K, et al. Serum levels of soluble secreted alpha-klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis. Clin. Exp. Nephrol. 2012; 16: 722-729.
54. Akimoto T, Yoshizawa H, Watanabe Y, et al. Characteristics of urinary and serum soluble klotho protein in patients with different degrees of chronic kidney disease. BMC Nephrol. 2012; 13: 155.
55. Sugiura H, Tsuchiya K, Nitta K,. Circulating levels of soluble alpha-klotho in patients with chronic kidney disease. Clin. Exp. Nephrol. 2011; 15: 795-796.
56. van Ark J, Hammes H, van Dijk MC, et al. Circulating alpha-klotho levels are not disturbed in patients with type 2 diabetes with and without macrovascular disease in the absence of nephropathy. Cardiovasc. Diabetol. 2013; 12: 116.
57. Amitani M, Asakawa A, Amitani H, et al. Plasma klotho levels decrease in both anorexia nervosa and obesity. Nutrition 2013; 29: 1106-1109.
58. Jeong SJ, Song JE, Kim SB, et al. Plasma klotho levels were inversely associated with subclinical carotid Atherosclerosis in HIV-infected patients receiving combined antiretroviral therapy. AIDS Res. Hum. Retroviruses 2013; 29: 1575-1581.
59. Pedersen L, Pedersen SM, Brasen CL, Rasmussen LM,. Soluble serum klotho levels in healthy subjects. Comparison of two different immunoassays. Clin. Biochem. 2013; 46: 1079-1083.
60. Lam-Rachlin J, Romero R, Korzeniewski SJ, et al. Infection and smoking are associated with decreased plasma concentration of the anti-aging protein, alpha-klothoa. J. Perinat. Med. 2013; 41: 581-594.
61. Neidert MC, Sze L, Zwimpfer C, et al. Soluble alpha-klotho: A novel serum biomarker for the activity of GH-producing pituitary adenomas. Eur. J. Endocrinol. 2013; 168: 575-583.
62. Siahanidou T, Garatzioti M, Lazaropoulou C, et al. Plasma soluble alpha-klotho protein levels in premature and term neonates: Correlations with growth and metabolic parameters. Eur. J. Endocrinol. 2012; 167: 433-440.
63. Sze L, Bernays RL, Zwimpfer C, Wiesli P, Brandle M, Schmid C,. Excessively high soluble klotho in patients with acromegaly. J. Intern. Med. 2012; 272: 93-97.
64. Semba RD, Cappola AR, Sun K, et al. Plasma klotho and mortality risk in older community-dwelling adults. J. Gerontol. A. Biol. Sci. Med Sci. 2011; 66: 794-800.
65. Ohata Y, Arahori H, Namba N, et al. Circulating levels of soluble alpha-klotho are markedly elevated in human umbilical cord blood. J. Clin. Endocrinol. Metab. 2011; 96: E943-947.
66. Carpenter TO, Insogna KL, Zhang JH, et al. Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: Circadian variance, effects of treatment, and relationship to parathyroid status. J. Clin. Endocrinol. Metab. 2010; 95: E352-357.
67. Naveh-Many T, Rahamimov R, Livni N, Silver J,. Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. J. Clin. Invest. 1995; 96: 1786-1793.
68. Kilav R, Silver J, Naveh-Many T,. Parathyroid hormone gene expression in hypophosphatemic rats. J. Clin. Invest. 1995; 96: 327-333.
69. Biber J, Hernando N, Forster I, Murer H,. Regulation of phosphate transport in proximal tubules. Pflugers Arch. 2009; 458: 39-52.
70. Forster IC, Hernando N, Biber J, Murer H,. Proximal tubular handling of phosphate: A molecular perspective. Kidney Int. 2006; 70: 1548-1559.
71. Miyamoto K, Haito-Sugino S, Kuwahara S, et al. Sodium-dependent phosphate cotransporters: Lessons from gene knockout and mutation studies. J. Pharm. Sci. 2011; 100: 3719-3730.
72. Biber J, Hernando N, Forster I,. Phosphate transporters and their function. Annu. Rev. Physiol. 2013; 75: 535-550.
73. Prie D, Urena Torres P, Friedlander G,. Latest findings in phosphate homeostasis. Kidney Int. 2009; 75: 882-889.
74. Shimada T, Yamazaki Y, Takahashi M, et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am. J. Physiol. Renal Physiol. 2005; 289: F1088-1095.
75. Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Invest. 2004; 113: 561-568.
76. Hu MC, Shi M, Zhang J, et al. Klotho: A novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J. 2010; 24: 3438-3450.
77. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al. The parathyroid is a target organ for FGF23 in rats. J. Clin. Invest. 2007; 117: 4003-4008.
78. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB,. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003; 64: 2272-2279.
79. Liu S, Quarles LD,. How fibroblast growth factor 23 works. J. Am. Soc. Nephrol. 2007; 18: 1637-1647.
80. Vervloet MG, van Ittersum FJ, Buttler RM, Heijboer AC, Blankenstein MA, ter Wee PM,. Effects of dietary phosphate and calcium intake on fibroblast growth factor-23. Clin. J. Am. Soc. Nephrol. 2011; 6: 383-389.
81. Moe SM, Zidehsarai M, Chambers MA, et al. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2011; 6: 257-264.
82. Gutierrez OM, Isakova T, Smith K, Epstein M, Patel N, Wolf M,. Racial differences in postprandial mineral ion handling in health and in chronic kidney disease. Nephrol. Dial. Transplant. 2010; 25: 3970-3977.
83. Razzaque MS,. The FGF23-klotho axis: Endocrine regulation of phosphate homeostasis. Nat. Rev. Endocrinol. 2009; 5: 611-619.
84. Yu X, Ibrahimi OA, Goetz R, et al. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology 2005; 146: 4647-4656.
85. Liu S, Vierthaler L, Tang W, Zhou J, Quarles LD,. FGFR3 and FGFR4 do not mediate renal effects of FGF23. J. Am. Soc. Nephrol. 2008; 19: 2342-2350.
86. Farrow EG, Davis SI, Summers LJ, White KE,. Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J. Am. Soc. Nephrol. 2009; 20: 955-960.
87. Slatopolsky E,. The intact nephron hypothesis: The concept and its implications for phosphate management in CKD-related mineral and bone disorder. Kidney Int. Suppl. 2011; 121: S3-8.
88. Craver L, Marco MP, Martinez I, et al. Mineral metabolism parameters throughout chronic kidney disease stages 1-5-achievement of K/DOQI target ranges. Nephrol. Dial. Transplant. 2007; 22: 1171-1176.
89. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int. 2007; 71: 31-38.
90. Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011; 79: 1370-1378.
91. Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 2008; 359: 584-592.
92. Isakova T, Xie H, Yang W, et al., and Chronic Renal Insufficiency Cohort Study Group. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 2432-2439.
93. Kendrick J, Cheung AK, Kaufman JS, et al. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J. Am. Soc. Nephrol. 2011; 22: 1913-1922.
94. Nakano C, Hamano T, Fujii N, et al. Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis. Bone 2012; 50: 1266-1274.
95. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J. Clin. Invest. 2011; 121: 4393-4408.
96. Shalhoub V, Shatzen EM, Ward SC, et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J. Clin. Invest. 2012; 122: 2543-2553.
97. Koh N, Fujimori T, Nishiguchi S, et al. Severely reduced production of klotho in human chronic renal failure kidney. Biochem. Biophys. Res. Commun. 2001; 280: 1015-1020.
98. Aizawa H, Saito Y, Nakamura T, et al. Downregulation of the klotho gene in the kidney under sustained circulatory stress in rats. Biochem. Biophys. Res. Commun. 1998; 249: 865-871.
99. Palomino HL, Rifkin DE, Anderson C, Criqui MH, Whooley MA, Ix JH,. 24-hour urine phosphorus excretion and mortality and cardiovascular events. Clin. J. Am. Soc. Nephrol. 2013; 8: 1202-1210.
100. Dominguez JR, Shlipak MG, Whooley MA, Ix JH,. Fractional excretion of phosphorus modifies the association between fibroblast growth factor-23 and outcomes. J. Am. Soc. Nephrol. 2013; 24: 647-654.
101. Seiler S, Rogacev KS, Roth HJ, et al. Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4. Clin. J. Am. Soc. Nephrol. 2014; 9: 1049-1058.
102. Hu MC, Shi M, Zhang J, Quinones H, Kuro-o M, Moe OW,. Klotho deficiency is an early biomarker of renal ischemia-reperfusion injury and its replacement is protective. Kidney Int. 2010; 78: 1240-1251.
103. Sugiura H, Yoshida T, Tsuchiya K, et al. Klotho reduces apoptosis in experimental ischaemic acute renal failure. Nephrol. Dial. Transplant. 2005; 20: 2636-2645.
104. Moreno JA, Izquierdo MC, Sanchez-Nino MD, et al. The inflammatory cytokines TWEAK and TNFalpha reduce renal klotho expression through NFkappaB. J. Am. Soc. Nephrol. 2011; 22: 1315-1325.
105. Hu MC, Moe OW,. Klotho as a potential biomarker and therapy for acute kidney injury. Nat. Rev. Nephrol. 2012; 8: 423-429.
106. Sugiura H, Yoshida T, Mitobe M, et al. Klotho reduces apoptosis in experimental ischaemic acute kidney injury via HSP-70. Nephrol. Dial. Transplant. 2010; 25: 60-68.
107. Ohyama Y, Kurabayashi M, Masuda H, et al. Molecular cloning of rat klotho cDNA: Markedly decreased expression of klotho by acute inflammatory stress. Biochem. Biophys. Res. Commun. 1998; 251: 920-925.
108. Tang C, Pathare G, Michael D, Fajol A, Eichenmuller M, Lang F,. Downregulation of klotho expression by dehydration. Am. J. Physiol. Renal Physiol. 2011; 301: F745-750.
109. Doi S, Zou Y, Togao O, et al. Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J. Biol. Chem. 2011; 286: 8655-8665.
110. Sugiura H, Yoshida T, Shiohira S, et al. Reduced klotho expression level in kidney aggravates renal interstitial fibrosis. Am. J. Physiol. Renal Physiol. 2012; 302: F1252-1264.
111. Forbes JM, Hewitson TD, Becker GJ, Jones CL,. Ischemic acute renal failure: Long-term histology of cell and matrix changes in the rat. Kidney Int. 2000; 57: 2375-2385.
112. Touyz RM,. Molecular and cellular mechanisms in vascular injury in hypertension: Role of angiotensin II. Curr. Opin. Nephrol. Hypertens. 2005; 14: 125-131.
113. de Cavanagh EM, Inserra F, Ferder L,. Angiotensin II blockade: A strategy to slow ageing by protecting mitochondria? Cardiovasc. Res. 2011; 89: 31-40.
114. Weber MA, Neutel JM, Smith DH,. Circulatory and extracirculatory effects of angiotensin-converting enzyme inhibition. Am. Heart J. 1992; 123: 1414-1420.
115. Kang PM, Landau AJ, Eberhardt RT, Frishman WH,. Angiotensin II receptor antagonists: A new approach to blockade of the renin-angiotensin system. Am. Heart J. 1994; 127: 1388-1401.
116. Zhou Q, Lin S, Tang R, Veeraragoo P, Peng W, Wu R,. Role of fosinopril and valsartan on klotho gene expression induced by angiotensin II in rat renal tubular epithelial cells. Kidney Blood Press. Res. 2010; 33: 186-192.
117. Mitani H, Ishizaka N, Aizawa T, et al. In vivo klotho gene transfer ameliorates angiotensin II-induced renal damage. Hypertension 2002; 39: 838-843.
118. Tang R, Zhou QL, Ao X, Peng WS, Veeraragoo P, Tang TF,. Fosinopril and losartan regulate klotho gene and nicotinamide adenine dinucleotide phosphate oxidase expression in kidneys of spontaneously hypertensive rats. Kidney Blood Press. Res. 2011; 34: 350-357.
119. Tang R, Zhou Q, Liu Z, Xiao Z, Pouranan V,. Effects of fosinopril and losartan on renal klotho expression and oxidative stress in spontaneously hypertensive rats. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2011; 36: 27-33.
120. Fukui T, Munemura C, Maeta S, Ishida C, Murawaki Y,. The effects of olmesartan and alfacalcidol on renoprotection and klotho gene expression in 5/6 nephrectomized spontaneously hypertensive rats. Yonago Acta Med. 2011; 54: 49-58.
121. Zanchi C, Locatelli M, Benigni A, et al. Renal expression of FGF23 in progressive renal disease of diabetes and the effect of ace inhibitor. PLoS ONE 2013; 8: e70775.
122. Arking DE, Krebsova A, Macek M, et al. Association of human aging with a functional variant of klotho. Proc. Natl Acad. Sci. U.S.A. 2002; 99: 856-861.
123. Arking DE, Becker DM, Yanek LR, et al. Klotho allele status and the risk of early-onset occult coronary artery disease. Am. J. Hum. Genet. 2003; 72: 1154-1161.
124. Narumiya H, Sasaki S, Kuwahara N, et al. HMG-CoA reductase inhibitors up-regulate anti-aging klotho mRNA via RhoA inactivation in IMCD3 cells. Cardiovasc. Res. 2004; 64: 331-336.
125. Yoon HE, Lim SW, Piao SG, Song JH, Kim J, Yang CW,. Statin upregulates the expression of klotho, an anti-aging gene, in experimental cyclosporine nephropathy. Nephron Exp. Nephrol. 2012; 120: e123-e133.
126. Wang Y, Kuro-o M, Sun Z,. Klotho gene delivery suppresses Nox2 expression and attenuates oxidative stress in rat aortic smooth muscle cells via the cAMP-PKA pathway. Aging Cell 2012; 11: 410-417.
127. Saito Y, Nakamura T, Ohyama Y, et al. In vivo klotho gene delivery protects against endothelial dysfunction in multiple risk factor syndrome. Biochem. Biophys. Res. Commun. 2000; 276: 767-772.